Human IgG4: a structural perspective

Anna M Davies, Brian J Sutton, Anna M Davies, Brian J Sutton

Abstract

IgG4, the least represented human IgG subclass in serum, is an intriguing antibody with unique biological properties, such as the ability to undergo Fab-arm exchange and limit immune complex formation. The lack of effector functions, such as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, is desirable for therapeutic purposes. IgG4 plays a protective role in allergy by acting as a blocking antibody, and inhibiting mast cell degranulation, but a deleterious role in malignant melanoma, by impeding IgG1-mediated anti-tumor immunity. These findings highlight the importance of understanding the interaction between IgG4 and Fcγ receptors. Despite a wealth of structural information for the IgG1 subclass, including complexes with Fcγ receptors, and structures for intact antibodies, high-resolution crystal structures were not reported for IgG4-Fc until recently. Here, we highlight some of the biological properties of human IgG4, and review the recent crystal structures of IgG4-Fc. We discuss the unexpected conformations adopted by functionally important Cγ2 domain loops, and speculate about potential implications for the interaction between IgG4 and FcγRs.

Keywords: Fc receptor; IgG1; IgG4; antibody; immunoglobulin.

© 2015 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.

Figures

Fig. 1
Fig. 1
Overall IgG architecture. (A) Schematic of an IgG antibody. The Fc fragment, comprising Cγ2 and Cγ3 domains from the heavy chain, is connected to the Cγ1 domain of each Fab fragment through a hinge region. The sequence composition of the hinge, and number of inter-heavy chain disulfide bonds varies between the four human IgG subclasses. In this figure, two inter-heavy chain disulfide bonds are indicated for IgG1. The variable regions of the Fab fragment (VH and VL) are responsible for antigen recognition. (B) Crystal structure of an intact human IgG1 antibody, solved at 2.7 Å resolution, reveals an asymmetric conformation (36). (C) Cartoon representation of the IgG-Fc fragment (50), showing the internal oligosaccharide moiety. The figure was prepared with PyMOL (166).
Fig. 2
Fig. 2
IgG utilizes the Cγ2–Cγ3 domain interface to interact with a variety of different proteins. (A) The neonatal receptor, FcRn (63). (B) HSV-1 (herpes simplex virus type I) gE-gI receptor (53). (C) Streptococcal protein G (52). (D) TRIM21 (tripartite motif-containing 21) (61). (E) Fab fragment from an IgM rheumatoid factor (74). (F) Fc–Fc interactions revealed by crystal packing (18). (G) Staphylococcal protein A (49). (H) Fc–Fc-mediated hexamer involved in complement activation (19,36,90). The figure was prepared with PyMOL (167).
Fig. 3
Fig. 3
Overall structure of IgG1-Fc/FcγR complexes. (A) Crystal structure of the IgG1-Fc/FcγRIIIa complex (57). The domain arrangement is similar in the IgG1-Fc/FcγRIIa (60), FcγRIIb (65) and FcγRIIIb (56,59) complexes. (B) Crystal structure of the IgG1-Fc/FcγRI complex (55). In both panels, receptor domains are labeled D1-D3 and IgG-Fc domains Cγ2–Cγ3. The figure was prepared with PyMOL (167).
Fig. 4
Fig. 4
Sites of interaction in IgG1-Fc/FcγR complexes. A crystal structure for IgG1-Fc in complex with FcγRIIIa (58) is shown, although the interface is similar in all FcγRs. One IgG1-Fc Cγ2 domain (blue) interacts with the receptor (yellow) D1-D2 domain linker and D2 domain BC loop. The second IgG1-Fc Cγ2 domain (pink) interacts with the D2 domain C and C′ strands. The lower hinge contacts the D2 domain BC and FG loops. The figure was prepared with PyMOL (167).
Fig. 5
Fig. 5
IgG1-Fc interactions with FcγRs. (A) The hydrophobic proline sandwich interaction, in which Pro329 from the Cγ2 FG loop interacts with two conserved tryptophan residues from the receptor. A position adjacent to the proline sandwich is a site of sequence variation, in which structurally equivalent residues are Arg102 in FcγRI (white) (54), Ser88 in FcγRII (pink) (65), and Ile88 in FcγRIII (beige) (58). In the FcγRI complex, Arg102 forms a hydrogen bond with the Pro329 backbone carbonyl group. (B) A second site of interaction involves the IgG1 Cγ2 domain BC and DE loops. In one IgG1-Fc/FcγRI complex (54), Lys142 from the receptor packs against Tyr296 (Cγ2 DE loop) while Lys145 from the receptor forms a hydrogen bond with Glu269 (Cγ2 BC loop). (C) In the IgG1-Fc/FcγRIIIa complex (58), the lower hinge from one IgG1 chain rests above a shallow groove created by His119, Lys120, His134, and His135 from the receptor. (D) In the IgG1-Fc/FcγRIIIa complex (58), the lower hinge from the second IgG1 chain is positioned above a depression created by Thr116, Ala117, Val158, and Lys161 from the receptor. (E) The position of the lower hinge differs in the two IgG1-Fc/FcγRI complexes. In one structure (white) (54), the lower hinge adopts a conformation akin to that in FcγRII and FcγRIII complexes, while in another structure (pink) (55), the hinge points away from the Fc region. (F) In one IgG1-Fc/FcγRI complex (55), Leu235 from the lower hinge occupies a hydrophobic pocket on the receptor. The figure was prepared with PyMOL (167).
Fig. 6
Fig. 6
Fab-arm exchange. (A) Two intact IgG4 antibodies with different specificities are indicated by different colors for the variable domains. (B) Antibodies separate into ‘half-molecules’, each comprising one heavy and one light chain. (C) Half-molecules recombine to form bi-specific antibodies. (D) Amino acid sequence of the IgG1 and IgG4 hinges (168). In IgG4, position 228 is serine, compared with proline in IgG1. Inter-chain disulfide bonds form between Cys226 and Cys229 in IgG1, while intra-chain disulfide bonds can form in IgG4.
Fig. 7
Fig. 7
IgG4-Fc structure. (A) Crystal structure of the IgG4 Cγ3 domain dimer (17). The two Cγ3 domains are colored in light and dark gray, and the position of Arg409 at the Cγ3–Cγ3 interface is colored pink. (B) Arg409 adopts two conformations at the Cγ3–Cγ3 interface. One conformation (pink) is compatible with a conserved network of four water molecules, of which one is shown. The second conformation (white) disrupts the conserved network. IgG1-Fc, in which residue 409 is lysine, is colored beige. Residues from the second Cγ3 domain are indicated by a prime symbol. (C) Overall structure of IgG4-Fc (18). The two chains are colored in light and dark gray. The oligosaccharide moiety from one chain is colored as follows: N-acetylglucosamine, yellow; mannose, pink; fucose, blue; galactose, green. The figure was prepared with PyMOL (167).
Fig. 8
Fig. 8
Conformational differences between IgG1 and IgG4 Cγ2 domain loops. (A) Overall structure of the IgG1 (yellow) (58) and IgG4 (green) (18) Cγ2 domain. While the overall domain structure is conserved, the conformation of BC and FG loops is different, and in IgG4, the FG loop folds away from the Cγ2 domain. (B) In IgG4 (blue) (18), Cα atoms for residues 327 (Gly in IgG4, Ala in IgG1) and Pro329 from the FG loop differ from their positions in IgG1 (white) (55) by approximately 6.7 and 9.9 Å, respectively. The positions of Asp270 and Pro271 from the BC loop are also significantly altered. (C) In IgG1 (55), the Asn325 side chain is able to form hydrogen bonds, indicated by black lines, with carbonyl oxygen atoms of Asp270 and Glu272 from the BC loop. (D) In IgG4 (18), Asn325 could instead form a hydrogen with the carbonyl oxygen atom of Pro271. The figure was prepared with PyMOL (167).
Fig. 9
Fig. 9
Disrupted FcγR and C1q binding sites in IgG4. (A) In all IgG1-Fc/FcγR complex structures, a hydrophobic ‘proline sandwich’ interaction forms between Pro329 from the IgG Cγ2 domain FG loop and two tryptophan residues from the receptor. The interaction between IgG1-Fc and FcγRIIIa is shown in gray (58). In IgG4-Fc (pink), the unique Cγ2 FG loop conformation would disrupt this conserved interaction (18). (B) Residues from IgG1-Fc (55) which are important for C1q binding are colored according to a model for the interaction between IgG1-Fc and C1q (164). The positions of Asp270 and Pro329 are indicated. (C) In IgG4-Fc (18), the positions of C1q binding residues are altered. The figure was prepared with PyMOL (167).
Fig. 10
Fig. 10
The IgG4 Cγ2 FG loop conformation is unique. The IgG1 Cγ2 FG loop (white) (50), IgE Cε3 FG loop (pink) (82), IgY Cυ3 FG loop (salmon) (153), IgM Cμ3 FG loop (yellow) (160), and IgA Cα2 FG loop (light green) (156) adopt a conserved conformation. The IgG4 Cγ2 FG loop conformation (dark green) (18), which contains a single proline residue at position 329, is unique. Residue numbering is according to the Protein Data Bank entry for each structure. The figure was prepared with PyMOL (167).
Fig. 11
Fig. 11
Deglycosylated IgG4-Fc crystal structure. (A) Two IgG4-Fc molecules (blue/yellow and green/pink) form an interlocked arrangement. (B) The Cγ2 domain FG loop forms crystal packing interactions and in the molecule colored pink, adopts the conserved conformation found in IgG1. The figure was prepared with PyMOL (167).
Fig. 12
Fig. 12
Cγ2 domain loop conformations. (A) In the IgG1-Fc/FcγRIIIa complex (light blue) (58), the conserved Cγ2 BC loop conformation precludes hydrogen bond formation between Asp270 (IgG1 Cγ2 BC loop) and a histidine residue from the receptor. In one IgG1-Fc/FcγRI complex (pink) (55), Pro271 isomerization alters the conformation of the BC loop, permitting hydrogen bond formation. (B) Four different combinations of Cγ2 BC and FG loop conformations are possible: yellow – conserved BC and FG loop, found in non-receptor-bound human IgG1 (e.g. (50)), blue – conserved BC loop and unique FG loop, found in deglycosylated IgG4-Fc (19), gray – non-conserved BC loop and conserved FG loop, found in one IgG1-Fc/FcγRI complex (55), purple – non-conserved BC loop and unique FG loop, found in IgG4-Fc (18). The figure was prepared with PyMOL (167).
Fig. 13
Fig. 13
Potential interactions between IgG4-Fc and FcγRs. (A) The IgG4 Cγ2 domain FG loop (pink) (18) disrupts the hydrophobic proline sandwich. The Pro329 carbonyl oxygen atom and the Ser330 side chain could form hydrogen bonds, indicated by black lines, with Arg102 from FcγRI (white) (55). Of the human IgG subclasses, Ser330 is unique to IgG4. (B) The conserved Cγ2 BC loop conformation found in IgG1 (light blue) (55) precludes hydrogen bond formation between Asp270 and His148 from FcγRI. The Cγ2 BC loop conformation in IgG4 (pink) (18), in which Pro271 undergoes a cis/trans isomerization, would enable Asp270 to form a hydrogen bond with His148 from FcγRI (white) (55). In one FcγRI complex structure, Pro271 from the IgG1 Cγ2 BC loop also undergoes a cis/trans isomerization (55). (C) The same cis/trans isomerization would enable Asp270 from the IgG4 Cγ2 BC loop (pink) (18) to form a salt bridge with Arg134 from FcγRIIb (white) (65). (D) In the IgG1-Fc/FcγRIIIa complex (white) (58), Glu269 from the Cγ2 BC loop forms a hydrogen bond with Lys131. Gln268 from the IgG4 Cγ2 BC loop (pink) (18) would also be able to form a hydrogen bond with Lys131. The figure was prepared with PyMOL (167).

References

    1. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 2009;39:469–477.
    1. Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology. 2002;105:9–19.
    1. van der Zee JS, van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4 antibodies. Clin Exp Immunol. 1986;64:415–422.
    1. van der Zee JS, van Swieten P, Aalberse RC. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol. 1986;137:3566–3571.
    1. Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol. 2007;25:1369–1372.
    1. Jiang X-R, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov. 2011;10:101–111.
    1. Brennan FR, et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs. 2010;2:233–255.
    1. Persselin JE, Stevens RH. Serum IgG4 anti-Fab antibodies in rheumatoid arthritis are constitutively expressed. Rheumatol Int. 1988;8:205–211.
    1. Chen L-F, Mo Y-Q, Ma J-D, Luo L, Zheng D-H, Dai L. Elevated serum IgG4 defines specific clinical phenotype of rheumatoid arthritis. Mediators Inflamm. 2014;2014 Article ID 635293.
    1. Chapuy-Regaud S, Nogueira L, Clavel C, Sebbag M, Vincent C, Serre G. IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clin Exp Immunol. 2005;139:542–550.
    1. Cohen PL, Cheek RL, Hadler JA, Yount WJ, Eisenberg RA. The subclass distribution of human IgG rheumatoid factor. J Immunol. 1987;139:1466–1471.
    1. van de Stadt LA, et al. Antibodies to IgG4 hinge can be found in rheumatoid arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation. Arthritis Rheum. 2014;66:1133–1140.
    1. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366:539–551.
    1. Pieringer H, Parzer I, Wöhrer A, Reis P, Oppl B, Zwerina J. IgG4- related disease: an orphan disease with many faces. Orphanet J Rare Dis. 2014;9:110.
    1. Karagiannis P, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest. 2013;123:1457–1474.
    1. Santos AF, et al. IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol. 2015;135:1249–1256.
    1. Davies AM, et al. Crystal structure of the human IgG4 CH3 dimer reveals the role of Arg409 in the mechanism of Fab-arm exchange. Mol Immunol. 2013;54:1–7.
    1. Davies AM, et al. Structural determinants of unique properties of human IgG4-Fc. J Mol Biol. 2014;426:630–644.
    1. Davies AM, Jefferis R, Sutton BJ. Crystal structure of deglycosylated human IgG4-Fc. Mol Immunol. 2014;62:46–53.
    1. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:00520.
    1. Canfield SM, Morrison SL. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med. 1991;173:1483–1491.
    1. van der Neut Kolfschoten M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317:1554–1557.
    1. Labrijn AF, et al. Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol. 2011;187:3238–3246.
    1. Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med. 1993;187:661–667.
    1. Xu Y, Oomen R, Klein MH. Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement. J Biol Chem. 1994;269:3469–3474.
    1. Jefferis R, et al. A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem J. 1990;268:529–537.
    1. Niwa R, et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods. 2005;306:151–160.
    1. Pincetic A, Maamary J, Ravetch JV. Therapeutic applications of sialylated IVIG. In: Taniguchi N, Endo T, Hart GW, Seeberger PH, Wong C-H, editors. Glycoscience: Biology and Medicine. Japan: Springer; 2015. pp. 1509–1515.
    1. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol. 2008;20:471–478.
    1. Anthony RM, Ravetch JV. A novel role for the IgG Fc Glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol. 2010;30:S9–S14.
    1. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670–673.
    1. Lu J, Ellsworth JL, Hamacher N, Oak SW, Sun PD. Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding. J Biol Chem. 2011;286:40608–40613.
    1. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med. 1995;1:237–243.
    1. Parekh RB, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985;316:452–457.
    1. Ercan A, et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010;62:2239–2248.
    1. Saphire EO, et al. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science. 2001;293:1155–1159.
    1. Wu Y, West AP, Jr, Kim HJ, Thornton ME, Ward AB, Bjorkman PJ. Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12. Cell Rep. 2013;5:1443–1455.
    1. Harris LJ, Larson SB, Hasel KW, McPherson A. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry. 1997;36:1581–1597.
    1. Harris LJ, Skaletsky E, McPherson A. Crystallographic structure of an intact IgG1 monoclonal antibody. J Mol Biol. 1998;275:861–872.
    1. Sandin S, Öfverstedt L-G, Wikström A-C, Wrange Ö, Skoglund U. Structure and flexibility of individual immunoglobulin G molecules in solution. Structure. 2004;12:409–415.
    1. Lu Y, et al. Solution conformation of wild-type and mutant IgG3 and IgG4 immunoglobulins using crystallohydrodynamics: possible implications for complement activation. Biophys J. 2007;93:3733–3744.
    1. Rayner LE, Kadkhodayi-Kholghi N, Heenan RK, Gor J, Dalby PA, Perkins SJ. The solution structure of rabbit IgG accounts for its interactions with the Fc receptor and complement C1q and its conformational stability. J Mol Biol. 2013;425:506–523.
    1. Abe Y, Gor J, Bracewell DG, Perkins SJ, Dalby PA. Masking of the Fc region is human IgG4 by constrained X-ray scattering modeling: implications for antibody function and therapy. Biochem J. 2010;432:101–111.
    1. Rayner LE, Hui GK, Gor J, Heenan RK, Dalby PA, Perkins SJ. The Fab conformations in the solution structure of human immunoglobulin G4 (IgG4) restrict access to its Fc region: implications for functional activity. J Biol Chem. 2014;289:20740–20756.
    1. Lilyestrom WG, Shire S, Scherer TM. Influence of the cosolute environment on IgG solution structure analyzed by small-angle X-ray scattering. J Phys Chem B. 2012;116:9611–9618.
    1. Gregory L, et al. The solution conformations of the subclasses of human IgG deduced from sedimentation and small angle X-ray scattering studies. Mol Immunol. 1987;24:821–829.
    1. Rayner LE, Hui GK, Gor J, Heenan RK, Dalby PA, Perkins SJ. The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands. J Biol Chem. 2015;290:8420–8438.
    1. Tian X, Vestergaard B, Thorolfsson M, Yang Z, Rasmussen HB, Langkilde AE. In-depth analysis of subclass-specific conformational preferences of IgG antibodies. IUCrJ. 2015;2:9–18.
    1. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry. 1981;20:2361–2370.
    1. Matsumiya S, et al. Corrigendum to “Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1” [J. Mol. Biol. 386/3 (2007) 767–779] J Mol Biol. 2011;408:1001.
    1. Duquerroy S, et al. Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation. J Mol Biol. 2007;368:1321–1331.
    1. Sauer-Eriksson AE, Kleywegt GJ, Uhlén M, Jones TA. Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure. 1995;3:265–278.
    1. Sprague ER, Wang C, Baker D, Bjorkman PJ. Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol. 2006;4:e148.
    1. Lu J, Chu J, Zou Z, Hamacher NB, Rixon MW, Sun PD. Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc Natl Acad Sci USA. 2015;112:833–838.
    1. Kiyoshi M, et al. Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. Nat Commun. 2015;6:6866.
    1. Radaev S, Motyka S, Fridman W-H, Sautes-Fridman C, Sun PD. The structure of a human type III Fcγ receptor in complex with Fc. J Biol Chem. 2001;276:16469–16477.
    1. Ferrara C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA. 2011;108:12669–12674.
    1. Mizushima T, et al. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells. 2011;16:1071–1080.
    1. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex. Nature. 2000;406:267–273.
    1. Ramsland PA, et al. Structural basis for FcγRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol. 2011;187:3208–3217.
    1. James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci USA. 2007;104:6200–6205.
    1. DeLano WL, Ultsch MH, de Vos AM, Wells JA. Convergent solutions to binding at a protein–protein interface. Science. 2000;287:1279–1283.
    1. Oganesyan V, et al. Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem. 2014;289:7812–7824.
    1. Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs. Mol Immunol. 2014;58:132–138.
    1. Mimoto F, et al. Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIaR131 and FcγRIIaH131. Protein Eng Des Sel. 2013;26:589–598.
    1. Ahmed AA, et al. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J Mol Biol. 2014;426:3166–3179.
    1. Crispin M, Yu X, Bowden TA. Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy. Proc Natl Acad Sci USA. 2013;110:E3544–E3546.
    1. Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua WF. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr. 2008;D64:700–704.
    1. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol. 2003;325:979–989.
    1. Idusogie EE, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164:4178–4184.
    1. Matsumiya S, et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol. 2007;368:767–779.
    1. Teplyakov A, Zhao Y, Malia TJ, Obmolova G, Gilliland GL. IgG2 Fc structure and the dynamic features of the IgG CH2–CH3 interface. Mol Immunol. 2013;56:131–139.
    1. Vafa O, et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods. 2014;65:114–126.
    1. Corper AL, et al. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody–antigen interaction. Nat Struct Biol. 1997;4:374–381.
    1. Feige MJ, Nath S, Catharino SR, Weinfurtner D, Steinbacher S, Buchner J. Structure of the murine unglycosylated IgG1 Fc fragment. J Mol Biol. 2009;391:599–608.
    1. Kolenko P, Dohnálek J, Dušková J, Skálová T, Collard R, Hašek J. New insights into intra- and intermolecular interactions of immunoglobulins: crystal structure of mouse IgG2b-Fc at 2.1-Å resolution. Immunology. 2009;126:378–385.
    1. Keeble AH, Khan Z, Forster A, James LC. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc Natl Acad Sci USA. 2008;105:6045–6050.
    1. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature. 1994;372:379–383.
    1. Martin WL, West AP, Jr, Gan L, Bjorkman PJ. Crystal structure at 2.8Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell. 2001;7:867–877.
    1. Girardi E, Holdom MD, Davies AM, Sutton BJ, Beavil AJ. The crystal structure of rabbit IgG-Fc. Biochem J. 2009;417:77–83.
    1. Holdom MD, et al. Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcεRI. Nat Struct Mol Biol. 2011;18:571–576.
    1. Dhaliwal B, et al. Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcεRI. Proc Natl Acad Sci USA. 2012;109:12686–12691.
    1. Garman SC, Wurzburg BA, Tarchevskaya SS, Kinet J-P, Jardetzky TS. Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcεRIα. Nature. 2000;406:259–266.
    1. Sutton BJ, Davies AM. Structure and dynamics of IgE-receptor interactions: FceRI and CD23/FceRII. Immunol Rev. 2015;268:222–235.
    1. Sondermann S, Pincetic A, Maamary J, Lammens K, Ravetch JV. General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci USA. 2013;110:9868–9872.
    1. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–725.
    1. McEwan WA, Mallery DL, Rhodes DA, Trowsdale J, James LC. Intracellular antibody-mediated immunity and the role of TRIM21. BioEssays. 2011;33:803–809.
    1. Zack DJ, Stempniak M, Wong AL, Weisbart RH. Localization of an Fc-binding reactivity to the constant region of human IgG4. Implications for the pathogenesis of rheumatoid arthritis. J Immunol. 1995;155:5057–5063.
    1. Kawa S, et al. A novel immunoglobulin-immunoglobulin interaction in autoimmunity. PLoS ONE. 2008;3:e1637.
    1. Diebolder CA, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343:1260–1263.
    1. Nordenfelt P, et al. Antibody orientation at bacterial surfaces is related to invasive infection. J Exp Med. 2012;209:2367–2381.
    1. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47.
    1. Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov. 2012;11:311–331.
    1. Malbec O, Daëron M. The mast cell IgG receptors and their roles in tissue inflammation. Immunol Rev. 2007;217:206–221.
    1. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14:94–108.
    1. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275–290.
    1. Nimmerjahn F, Ravetch JV. Fcγ receptors: old friends and new family members. Immunity. 2006;24:19–28.
    1. Bruhns P, et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113:3716–3725.
    1. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood. 2012;119:5640–5649.
    1. Smith KGC, Clatworthy RM. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;10:343.
    1. Nimmerjahn F, Ravetch JV. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun. 2012;12:13.
    1. Reddy MP, et al. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol. 2000;164:1925–1933.
    1. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci. 2009;30:356–362.
    1. Shields RL, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem. 2001;276:6591–6604.
    1. Hayes JM, et al. Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions. J Proteome Res. 2014;13:5471–5485.
    1. Galon J, et al. Affinity of the interaction between Fc gamma receptor type III (FcγRIII) and monomeric human IgG subclasses. Role of FcγRIII glycosylation. Eur J Immunol. 1997;27:1928–1932.
    1. Radaev S, Sun P. Recognition of immunoglobulins by Fcγ receptors. Mol Immunol. 2001;38:1073–1083.
    1. Hanson QM, Barb AW. A perspective on the structure and receptor binding properties of immunoglobulin G Fc. Biochemistry. 2015;54:2931–2942.
    1. Woof JM, Burton DR. Human antibody–Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol. 2004;4:89–99.
    1. Okazaki A, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa. J Mol Biol. 2004;336:1239–1249.
    1. Maenaka K, van der Merwe P, Stuart D, Jones EY, Sondermann P. The human low affinity Fcγ receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J Biol Chem. 2001;276:44898–44904.
    1. Powell MS, et al. Biochemical analysis and crystallisation of FcγRIIa, the low affinity receptor for IgG. Immunol Lett. 1999;68:17–23.
    1. Bloom JW, Madanat MS, Marriott D, Wong T, Chan SY. Intrachain disulfide bond in the core hinge region of human IgG4. Prot Sci. 1997;6:407–415.
    1. Rispens T, Ooijevaar-de Heer P, Bende O, Aalberse RC. Mechanism of immunoglobulin G4 Fab-arm exchange. J Am Chem Soc. 2011;133:10302–10311.
    1. Schuurman J, Perdok GJ, Gorter AD, Aalberse RC. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol. 2001;38:1–8.
    1. Young E, Lock E, Ward DG, Cook A, Harding S, Wallis GLF. Estimation of polyclonal IgG4 hybrids in normal human serum. Immunology. 2014;142:406–413.
    1. Rose RJ, et al. Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure. 2011;19:1274–1282.
    1. Hamid O, et al. Safety and tumor responses with lambrolizumab (Anti–PD-1) in melanoma. N Engl J Med. 2013;369:134–144.
    1. Wang C, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2:846–856.
    1. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207–212.
    1. Labrijn AF, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009;27:767–771.
    1. Angal S, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol. 1993;30:105–108.
    1. Shapiro RI, et al. Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4. J Pharm Biomed Anal. 2011;55:168–175.
    1. Castro M, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125–1132.
    1. Ren R, Dao H., Jr Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. Clin Cosmet Invest Dermatol. 2013;6:75–80.
    1. Piper E, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41:330–338.
    1. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011;17:6417–6427.
    1. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8:205–217.
    1. Satoguina JS, Weyand E, Larbi J, Hoerauf A. T regulatory-1 cells induce IgG4 production by B cells: role of IL-10. J Immunol. 2005;174:4718–4726.
    1. Jeannin P, Lecoanet S, Delneste Y, Gauchat J-F, Bonnefoy J-Y. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol. 1998;160:3555–3561.
    1. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet. 2001;357:752–756.
    1. Jönsson F, Daëron M. Mast cells and company. Front Immunol. 2012;3:16.
    1. Zhao W, Kepley CL, Morel PA, Okumoto LM, Fukuoka Y, Schwartz LB. FcγRIIa, not FcγRIIb, is constitutively and functionally expressed on skin-derived human mast cells. J Immunol. 2006;177:694–701.
    1. Jönsson F, et al. Human FcγRIIA induces anaphylactic and allergic reactions. Blood. 2012;119:2533–2544.
    1. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004;113:1025–1034.
    1. Strait RT, Morris SC, Fred D, Finkelman FD. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and FcγRIIb cross-linking. J Clin Invest. 2006;116:833–841.
    1. Kepley CL, et al. Co-aggregation of FcγRII with FcεRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes. J Biol Chem. 2004;279:35139–35149.
    1. James LK, et al. Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. J Allergy Clin Immunol. 2012;130:663–670.
    1. Dodev TS, et al. Inhibition of allergen-dependent IgE activity by antibodies of the same specificity but different class. Allergy. 2015;70:720–724.
    1. Aalberse RC, van der Gaag R, van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol. 1983;130:722–726.
    1. Collins AM, Davies JM. Allergen capture by IgE and IgG. Enhanced cell-binding by allergen multimers: how complex is it? Immunol Cell Biol. 2013;91:115–117.
    1. Linnebacher M, Maletzki C. Tumor-infiltrating B cells: the ignored players in tumor immunology. OncoImmunology. 2012;1:1186–1188.
    1. Karagiannis P, Gilbert AE, Nestle FO, Karagiannis SN. IgG4 antibodies and cancer-associated inflammation: insights into a novel mechanism of immune escape. OncoImmunology. 2013;2:e24889.
    1. Germain C, Gnjatic S, Dieu-Nosjean M-C. Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity. Front Immunol. 2015;6:67.
    1. Harada K, et al. Significance of immunoglobulin G4 (IgG4)-positive cells in extrahepatic cholangiocarcinoma: molecular mechanism of IgG4 reaction in cancer tissue. Hepatology. 2012;56:157–164.
    1. Yoneda M, Inada H, Kanayama K, Shiraishi T. A case of pancreatic ductal adenocarcinoma with marked infiltration with IgG4-positive cells. J Cytol. 2013;30:46–48.
    1. Price MA, et al. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res. 2011;6:1148–1157.
    1. Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol. 1993;23:1098–1104.
    1. Pürzel J, Schmitt R, Viertlboeck BC, Göbel TW. Chicken IgY binds its receptor at the CH3/CH4 interface similarly as the human IgA:FcαRI interaction. J Immunol. 2009;183:4554–4559.
    1. Taylor AI, Sutton BJ, Calvert RA. Mutations in an avian IgY-Fc fragment reveal the locations of monocyte Fc receptor binding sites. Dev Comp Immunol. 2010;34:97–101.
    1. He Y, Bjorkman PJ. Structure of FcRY, an avian immunoglobulin receptor related to mammalian mannose receptors, and its complex with IgY. Proc Natl Acad Sci USA. 2011;108:12431–12436.
    1. Schreiner B, Viertlboeck BC, Göbel TW. A striking example of convergent evolution observed for the ggFcR:IgY interaction closely resembling that of mammalian FcR:IgG. Dev Comp Immunol. 2012;36:566–571.
    1. Taylor AI, Fabiane SM, Sutton BJ, Calvert RA. The crystal structure of an avian IgY-Fc fragment reveals conservation with both mammalian IgG and IgE. Biochemistry. 2009;48:558–562.
    1. Woof JM, Russell MW. Structure and function relationships in IgA. Mucosal Immunol. 2011;4:590–597.
    1. Ghumra A, et al. Structural requirements for the interaction of human IgM and IgA with the human Fcα/μ receptor. Eur J Immunol. 2009;39:1147–1156.
    1. Herr AB, Ballister ER, Bjorkman PJ. Insights into IgA-mediated immune responses from the crystal structures of human FcαRI and its complex with IgA1-Fc. Nature. 2003;423:614–620.
    1. Shibuya A, Honda S. Molecular and functional characteristics of the Fcα/μR, a novel Fc receptor for IgM and IgA. Springer Semin Immunopathol. 2006;28:377–382.
    1. Klimovich VB. IgM and its receptors: structural and functional aspects. Biochemistry (Mosc) 2011;76:534–549.
    1. Kubagawa H, et al. Identity of the elusive IgM Fc receptor (FcμR) in humans. J Exp Med. 2009;206:2779–2793.
    1. Müller R, et al. High-resolution structures of the IgM Fc domains reveal principles of its hexamer formation. Proc Natl Acad Sci USA. 2013;110:10183–10188.
    1. Nguyen DC, Sanghvi R, Scinicariello F, Pulit-Penaloza J, Hill N, Attanasio R. Cynomolgus and pigtail macaque IgG subclasses: characterization of IGHG genes and computational analysis of IgG/Fc receptor binding affinity. Immunogenetics. 2014;66:361–377.
    1. Hogarth PM, Anania JC, Wines BD. The FcγR of humans and non-human primates and their interaction with IgG: implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies. Curr Top Microbiol Immunol. 2014;382:321–352.
    1. Tao MH, Canfield SM, Morrison SL. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med. 1991;173:1025–1028.
    1. Isenman DE, Dorrington KJ, Painter RH. The structure and function of immunoglobulin domains. II. The importance of interchain disulfide bonds and the possible role of molecular flexibility in the interaction between immunoglobulin G and complement. J Immunol. 1975;114:1726–1729.
    1. Schneider S, Zacharias M. Atomic resolution model of the antibody Fc interaction with the complement C1q component. Mol Immunol. 2012;51:66–72.
    1. Duncan AR, Woof JM, Partridge LJ, Burton DR, Winter G. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature. 1988;332:563–564.
    1. Schrödinger, LLC; The PyMOL Molecular Graphics System, Version 1.1.
    1. Brekke OH, Michaelsen TE, Sandlie I. The structural requirements for complement activation by IgG: does it hinge on the hinge? Immunol Today. 1995;16:85–90.

Source: PubMed

3
订阅